The radiolabeled IONs presented in this study carried either one or both pharmacophores, a Glu-CO-Lys ligand, targeting PSMA and a bombesin peptide, targeting GRPr, for dual targeting of prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.